Atomoxetine versus methylphenidate in paediatric outpatients with attention deficit hyperactivity disorder: A randomized, double-blind comparison trial

Australian and New Zealand Journal of Psychiatry

Volumn 41, Issue 3, 2007, Pages 222-230

  Wang, Yufeng ^b   Zheng, Yi ^c   Du, Yasong ^d   Song, Dong ^e   Shin, Yee Jin ^e   Cho, Soo ^f   Kim, Bung ^f   Ahn, Dong ^g   Marquez Caraveo, Maria ^h   Gao, Haitao ^a   Williams, David ^a   Levine, Louise ^a  

^a ELI LILLY AND COMPANY   (United States)

^b PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d SHANGHAI MENTAL HEALTH CENTER   (China)

^e Yonsei University College of Medicine   (South Korea)

^f Seoul National University Hospital   (South Korea)

^g Hanyang University College of Medicine   (South Korea)

^h Hospital Psiquiatrico Infantil Dr Juan N Navarro   (Mexico)

Author keywords

Atomoxetine; Attention deficit hyperactivity disorder; Methylphenidate

Indexed keywords

ATOMOXETINE; METHYLPHENIDATE; PLACEBO;

ABDOMINAL PAIN; ADOLESCENT; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; ATTENTION DEFICIT DISORDER; BODY WEIGHT; CHICKENPOX; CHILD; CHILDHOOD DISEASE; CHINA; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CREATINE KINASE BLOOD LEVEL; DECREASED APPETITE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOCAL EPILEPSY; HEART PALPITATION; HEART RATE; HUMAN; INSOMNIA; IRRITABILITY; KOREA; MAJOR CLINICAL STUDY; MALE; MEXICO; MULTICENTER STUDY; NAUSEA; OUTPATIENT; PSYCHOLOGICAL RATING SCALE; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCORING SYSTEM; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; ADRENERGIC UPTAKE INHIBITORS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PERSONALITY ASSESSMENT; PROPYLAMINES;

EID: 34248149476     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670601057767     Document Type: Article

References (38)

1. Comings, DE. (2001) Clinical and molecular genetics of ADHD and Tourette syndrome. Two related polygenic disorders. Ann N Y Acad Sci, 931, pp. 50-83.
2. Goldman, LS, Genel, M. and Bezman, RJ (1998) Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association. J Am Med Assoc, 279, pp. 1100-1107.
3. Biederman, J. and Spencer, TJ. (1999) Attention-deficit/hyperactivity disorder (ADHD) as a noradrenergic disorder. Biol Psychiatry, 46, pp. 1234-1242.
4. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, American Psychiatric Association, Washington, DC
5. Barkley, RA, Fischer, M. and Smallish, L. (2002) The persistence of attention-deficit/hyperactivity disorder into young adulthood as a function of reporting source and definition of disorder. J Abnorm Psychol, 111, pp. 279-289.
6. Biederman, J., Newcorn, J. and Sprich, S. (1991) Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry, 148, pp. 564-577.
7. Klein, RG and Mannuzza, S. (1991) Long-term outcome of hyperactive children: A review. J Am Acad Child Adolesc Psychiatrics, 30, pp. 383-387.
8. MTA Cooperative Group (1999) A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Multimodal Treatment Study of Children with ADHD. Arch Gen Psychiatry, 56, pp. 1073-1086.
9. Ferris, RM and Tang, FL. (1979) Comparison of the effects of the isomers of amphetamine, methylphenidate and deoxypipradrol on the uptake of I-[3H]norepinephrine and [3H]dopamine by synaptic vesicles from rat whole brain, striatum and hypothalamus. J Pharmacol Exp Ther, 210, pp. 422-428.
10. Dodson, WW. (2005) Pharmacotherapy of adult ADHD. J Clin Psychol, 61, pp. 589-606.
11. Holman, RB. (1994) Biological effects of central nervous system stimulants. Addiction, 89, pp. 1435-1441.
12. Greenhill, L. (1995) Attention-deficit/hyperactivity disorder: The stimulants. Child Adolesc Psychiatr Clin N Am, 4, pp. 123-168.
13. Bymaster, FP, Katner, JS and Nelson, DL (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: A potential mechanism for efficacy in attention deficit/ hyperactivity disorder. Neuropsychopharmacology, 27, pp. 699-711.
14. Spencer, T., Biederman, J. and Wilens, T. (1996) Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry, 35, pp. 409-432.
15. Spencer, TJ, Biederman, J., Wilens, TE and Faraone, SV. (2002) Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry, 63, pp. 16-22.
16. Popper, CW. (1997) Antidepressants in the treatment of attention-deficit/ hyperactivity disorder. J Clin Psychiatry, 58, pp. 14-29.
17. Kelsey, DK, Sumner, CR and Casat, CD (2004) Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-controlled trial. Pediatrics, 114, pp. e1-e8.
18. Heil, SH, Holmes, HW and Bickel, WK (2002) Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend, 67, pp. 149-156.
19. Michelson, D., Faries, D. and Wernicke, J. (2001) Atomoxetine in the treatment of children and adolescents with attention-deficit/ hyperactivity disorder: A randomized, placebo-controlled, dose-response study. Pediatrics, 108, p. E83.
20. Michelson, D., Allen, AJ and Busner, J. (2002) Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study. Am J Psychiatry, 159, pp. 1896-1901.
21. Spencer, T., Heiligenstein, JH and Biederman, J. (2002) Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry, 63, pp. 1140-1147.
22. Michelson, D., Adler, L. and Spencer, T. (2003) Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biol Psychiatry, 53, pp. 112-120.
23. Weiss, M., Tannock, R. and Kratochvil, C. (2005) A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD. J Am Acad Child Adolesc Psychiatry, 44, pp. 647-655.
24. Starr, HL and Kemner, J. (2005) Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: Treatment outcomes in African-American children with ADHD. J Nat Med Assoc, 97, pp. 11S-16S.
25. Kratochvil, CJ, Heiligenstein, JH and Dittmann, R. (2002) Atomoxetine and methylphenidate treatment in children with ADHD: A prospective, randomized, open-label trial. J Am Acad Child Adolesc Psychiatry, 41, pp. 776-784.
26. Kaufman, J., Birmaher, B. and Brent, D. (1997) Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL): Initial reliability and validity data. J Am Acad Child Adolesc Psychiatry, 36, pp. 980-988.
27. DuPaul, GJ, Power, TJ and Anastopoulos, AD (1998) ADHD rating scale-IV checklists, norms, and clinical interpretation, pp. 28-42. The Guilford Press, New York
28. Guy, W. (1976) ECDEU assessment manual for psychopharmacology, revised, pp. 217-222. National Institute of Mental Health, Psychopharmacology Research Branch, Rockville, MD
29. Conners, CK. (1997) Conners' rating scales-revised, technical manual, Multi-Health Systems, Toronto, Ontario
30. Biederman, J., Heiligenstein, JH and Faries, DE (2002) (Atomoxetine ADHD Study Group). Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics, 110, p. e75.
31. Spencer, T., Biederman, J. and Wilens, T. (1998) Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry, 155, pp. 693-695.
32. Kratochvil, CJ, Bohac, D. and Harrington, M. (2001) An open-label trial of tomoxetine in pediatric attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacology, 11, pp. 167-170.
33. Stein, MA, Blondis, TA and Schnitzler, ER (1996) Methylphenidate dosing: twice daily versus three times daily. Pediatrics, 98, pp. 748-756.
34. Pelham, WE, Gnagy, EM and Burrows-Maclean, L. (2001) Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics, 107, p. E105.
35. Spencer, TJ, Newcorn, JH and Kratochvil, CJ (2005) Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit/hyperactivity disorder. Pediatrics, 116, pp. e74-e80.
36. Brown, WJ, Biederman, J. and Spencer, T. (2002) Efficacy and safety of atomoxetine in the treatment of attention deficit/hyperactivity disorder in children and adolescents. Eur Neuropsychopharmacol, 12, p. S411.
37. Greenhill, LL, Swanson, JM and Vitiello, B. (2001) Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry, 40, pp. 180-187.
38. Greenhill, LL, Abikoff, HB and Arnold, LE (1996) Medication treatment strategies in the MTA Study: Relevance to clinicians and researchers. J Am Acad Child Adolesc Psychiatry, 35, pp. 1304-1313.